干扰素视网膜病变继发于恶性黑色素瘤治疗

Clinical eye and vision care Pub Date : 1999-12-01 Epub Date: 1999-12-20 DOI:10.1016/S0953-4431(99)00040-5
Blair B Lonsberry, O.D
{"title":"干扰素视网膜病变继发于恶性黑色素瘤治疗","authors":"Blair B Lonsberry, O.D","doi":"10.1016/S0953-4431(99)00040-5","DOIUrl":null,"url":null,"abstract":"<div><p>Interferons<span><span><span> are a group of proteins that exhibit immunoregulatory and antiviral properties. </span>Interferon alpha<span><span> is now being commercially produced via recombinant DNA technology and has been indicated in the treatment of a variety of conditions including hepatitis, hairy cell leukemia, and has shown </span>antitumor activity in patients with </span></span>melanoma<span><span><span>. Treatment with interferon alpha is generally well tolerated, though certain side effects of continued treatment have been noted including anorexia, fever, fatigue, blood disorders<span>, GI symptoms, and central nervous symptoms. One particular side effect, that of </span></span>retinopathy<span>, has received scattered reports in the literature. Signs including cotton wool spots, hemorrhages, and </span></span>optic nerve fiber layer defects have been noted. The following report describes a patient undergoing interferon treatment, secondary to the removal of a malignant melanoma from her back and her subsequent development of retinopathy.</span></span></p></div>","PeriodicalId":80266,"journal":{"name":"Clinical eye and vision care","volume":"11 4","pages":"Pages 225-229"},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0953-4431(99)00040-5","citationCount":"0","resultStr":"{\"title\":\"Interferon retinopathy secondary to treatment for malignant melanoma\",\"authors\":\"Blair B Lonsberry, O.D\",\"doi\":\"10.1016/S0953-4431(99)00040-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Interferons<span><span><span> are a group of proteins that exhibit immunoregulatory and antiviral properties. </span>Interferon alpha<span><span> is now being commercially produced via recombinant DNA technology and has been indicated in the treatment of a variety of conditions including hepatitis, hairy cell leukemia, and has shown </span>antitumor activity in patients with </span></span>melanoma<span><span><span>. Treatment with interferon alpha is generally well tolerated, though certain side effects of continued treatment have been noted including anorexia, fever, fatigue, blood disorders<span>, GI symptoms, and central nervous symptoms. One particular side effect, that of </span></span>retinopathy<span>, has received scattered reports in the literature. Signs including cotton wool spots, hemorrhages, and </span></span>optic nerve fiber layer defects have been noted. The following report describes a patient undergoing interferon treatment, secondary to the removal of a malignant melanoma from her back and her subsequent development of retinopathy.</span></span></p></div>\",\"PeriodicalId\":80266,\"journal\":{\"name\":\"Clinical eye and vision care\",\"volume\":\"11 4\",\"pages\":\"Pages 225-229\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0953-4431(99)00040-5\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical eye and vision care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0953443199000405\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"1999/12/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical eye and vision care","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0953443199000405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"1999/12/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

干扰素是一组具有免疫调节和抗病毒特性的蛋白质。干扰素α现在正通过重组DNA技术进行商业化生产,并已被用于治疗各种疾病,包括肝炎、毛细胞白血病,并已显示出对黑色素瘤患者的抗肿瘤活性。用α干扰素治疗通常耐受性良好,尽管持续治疗的某些副作用已被注意到,包括厌食、发烧、疲劳、血液紊乱、胃肠道症状和中枢神经症状。一种特殊的副作用,即视网膜病变,在文献中得到了零星的报道。症状包括棉絮斑、出血和视神经纤维层缺损。以下报告描述了一名患者接受干扰素治疗,继发于她背部的恶性黑色素瘤切除和随后的视网膜病变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Interferon retinopathy secondary to treatment for malignant melanoma

Interferons are a group of proteins that exhibit immunoregulatory and antiviral properties. Interferon alpha is now being commercially produced via recombinant DNA technology and has been indicated in the treatment of a variety of conditions including hepatitis, hairy cell leukemia, and has shown antitumor activity in patients with melanoma. Treatment with interferon alpha is generally well tolerated, though certain side effects of continued treatment have been noted including anorexia, fever, fatigue, blood disorders, GI symptoms, and central nervous symptoms. One particular side effect, that of retinopathy, has received scattered reports in the literature. Signs including cotton wool spots, hemorrhages, and optic nerve fiber layer defects have been noted. The following report describes a patient undergoing interferon treatment, secondary to the removal of a malignant melanoma from her back and her subsequent development of retinopathy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书